Table 1. Clinical data of patients following hematopoietic stem cell transplantation (HSCT).
| Hematopoietic disease |
Patients (n=27) |
| AML |
37% (10) |
| B-NHL |
4% (1) |
| CLL |
7% (2) |
| CML |
15% (4) |
| MDS |
19% (5) |
| Multiple Myeloma |
4% (1) |
| T-cell lymphoma |
15% (4) |
| Transplant source |
| Bone marrow familiar-allogenic |
7% (2) |
| Bone marrow foreign-allogenic |
4% (1) |
| Peripheral stem cells familiar-allogenic |
56% (15) |
| Peripheral stem cells foreign-allogenic |
33% (9) |
| Sex-Missmatch |
48% (13) |
| Systemic GvHD |
| Liver |
15% (4) |
| Intestine |
19% (5) |
| Oral |
41% (11) |
| Cutaneous |
81% (22) |
| Ocular |
67% (18) |
| Systemic Immunosuppression |
56% (15) |
| Mycophenolate |
7% (2) |
| Ciclosporin |
26% (7) |
| Everolimus |
15% (4) |
| Sirolimus |
7% (2) |
| Systemic Steroids (2,5 - 17,5 mg prednisolone /d) |
48% (13) |
Table 1 of
Eberwein, Mol Vis 2013; 19:1492-1501.